Programmed death-ligand 1 mRNA (PD-L1 mRNA)

Programmed death-ligand 1 (PD-L1), encoded by the CD274 gene, is a critical transmembrane protein that serves as a primary inhibitory checkpoint in the immune system [1]. Its biological function involves binding to the PD-1 receptor on T-cells to deliver suppressive signals that maintain self-tolerance and prevent autoimmunity [2]. In many malignancies, cancer cells overexpress PD-L1 to exploit this pathway, effectively silencing the host's anti-tumor immune response and facilitating immune evasion [4]. Targeting the PD-L1 mRNA with a small interfering RNA (siRNA) payload is a therapeutic strategy designed to downregulate PD-L1 expression at the post-transcriptional level [3]. By inducing the degradation of the mRNA transcript via the RNA interference (RNAi) machinery, this approach prevents the synthesis of the PD-L1 protein, thereby reducing its density on the cell surface and restoring T-cell mediated cytotoxicity against the tumor [3][4]. This modality is particularly promising for its potential to achieve more durable silencing compared to protein-blocking antibodies and is currently being explored in various clinical and preclinical oncology settings [3].

Other names

CD274 mRNAB7-H1 mRNAProgrammed cell death 1 ligand 1 mRNAB7 homolog 1 mRNA

The siRNA payload utilizes the RNA interference (RNAi) pathway to bind complementarily to the PD-L1 mRNA sequence, leading to its cleavage by the RNA-induced silencing complex (RISC) and subsequent degradation, which prevents the translation of the PD-L1 protein [3].